Abstract
Aortic (valve) stenosis (AS) is an obstruction to blood ejection from the left ventricle (LV) due to a fixed or dynamic stenosis located in the aortic valve, either over (supravalvular) or below it (subvalvular) [1]. AS is the most frequent form and accounts for the majority of congenital forms and for all of the acquired forms. AS is also the most frequent valvular heart disease in Western countries. In the Cardiovascular Health Study (5201 men and women over the age of 65), 26% of study participants had a thickening of the valve or calcification without significant obstruction, with a slight predominance of the disorder noted in men; 2% of all patients had frank AS [2]. Prevalence of aortic sclerosis increases with age: 20% in patients aged 65–75, 35% in those aged 75–85, and 48% in patients older than 85, while frank AS for the same age groups was 1–3%, 2–4%, and 4%, respectively. The most common cause is degenerative calcific valvular disease, with an incidence of 2–7% in the population over the age of 65 [3]. The mechanism by which a tricuspid aortic valve becomes stenotic is judged to be similar to that of atherosclerosis, as the initial plaque of AS is like that in coronary artery disease [4]. Risk factors commonly associated with coronary artery disease—including age, male gender, hyperlipidemia, evidence of active inflammation—seem to play a role in the development of AS, and both diseases are often present in the same individual [5–7]. Though debated, the use of statins is thought to slow the early progression of AS, while it is ineffective in the late course of the disease [8–11]. The initial and further evolution of AS usually occurs in the sixth, seventh, and eighth decades of life. The characteristic morphological appearance of the calcific AS consists in the presence of fibrous and calcific tissue on thickened cusps, preventing valve opening during outflow (Fig. 14.1). Calcific AS is determined mainly by solid calcium deposits in the valve cusps rather than fusion of the commissures, and calcification starts in the fibrous part of the valve. The stratified microscopic structure is usually preserved. The process of calcific aortic valve degeneration is secondary to inflammatory and proliferative changes, with accumulation of lipids, hyperactivity of angiotensin-converting enzymes, and infiltration of macrophages and T lymphocytes [12, 13]. These lesions involve the typical early chronic inflammatory cell infiltrates (macrophages and T lymphocytes) as the first ultrastructural changes, and lipid deposits and fibrotic thickening with collagen and elastin [14, 15].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rahimtoola SH. Aortic valve disease. In: Fuster V, Alexander RW, O’Ruourke RA, editors. Hurst’s the heart. 11th ed. New York: McGraw Hill; 2004. p. 1987–2000.
Supino PG, Borer JS, Preibisz J, Bornstein A. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail Clin. 2006;2:379–93.
Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J. 2007;28:230–68.
Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis: histological and immunohistochemical studies. Circulation. 1994;90:844–53.
Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5.
Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7.
Taylor HA Jr, Clark BL, Garrison RJ, et al. Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol. 2005;95:401–4.
Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004;110:1180–2.
Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–9.
Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97.
Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554–6.
Olsonn M, Thyberg J, Nilsson J. Presence of oxidized low-density lipoproteins in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218.
O’Brien KD, Shavelle DM, Caulfield MT, et al. Association of ACE with low density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106:2224–30.
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression and treatment strategy. Circulation. 2005;111:3316–26.
Olsson N, Delsgaaro CJ, Haegerstrand A, et al. Accumulation of T-lymphocytes and expression of interleukin-2 receptor in non-rheumatic stenotic aortic valves. J Am Coll Cardiol. 1994;23:1162–70.
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111:920–5.
Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaortic stenosis, bicuspid aortic valve, supravalvular aortic stenosis, and coarctation of the aorta. Circulation. 2006;114:2412–22.
Keane JF, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects: results of treatment of patients with aortic valvular stenosis. Circulation. 1993;87:116–27.
Donner R, Carabello BA, Black I, Spann JF. Left ventricular wall stress in compensated aortic stenosis in children. Am J Cardiol. 1983;51:946–51.
Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2006;48:1–148.
Tobin JR Jr, Rahimtoola SH, Blundell PE, et al. Percentage of left ventricular stroke work loss: a simple hemodynamic concept for estimation of severity in valvular aortic stenosis. Circulation. 1967;35:868–79.
Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. Circulation. 1993;87:73–6.
Braunwald E, Fraham CJ. Studies on the Starling’s law of the heart. IV. Observation on hemodynamic functions of the left atrium in man. Circulation. 1961;24:633–42.
Ross J Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis. 1976;18:255–64.
Huber D, Grimm J, Koch R, et al. Determinants of ejection performance in aortic stenosis. Circulation. 1981;64:126–34.
Johnson LL, Sciacca RR, Ellis K, et al. Reduced left ventricular myocardial blood flow per unit mass in aortic stenosis. Circulation. 1978;57:582–90.
Marcus ML, Doty DB, Horatzka LF, et al. Decreased coronary reserve. A mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med. 1982;46:1362–6.
Gould KL, Carabello BA. Why angina in aortic stenosis with normal coronary arteriograms? Circulation. 2003;107:3121–3.
Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38:61–7.
Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;53:332–41.
Koide M, Nagatsu M, Zile MR, et al. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation. 1997;95:1349–51.
Rogers JH, Tamirisa P, Kovacs A, et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to overload. J Clin Invest. 1999;104:567–76.
Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101:2863–9.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:1561–6.
Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS. Tolerance of the hypertrophic heart to ischemia: studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation. 1990;81:1644–53.
Marcus ML, Doty DB, Hiratzka LF, Wright CB, Eastham CL. Decreased coronary reserve: a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med. 1982;307:1362–6.
Breisch EA, White FC, Bloor CM. Myocardial characteristics of pressure overload hypertrophy: a structural and functional study. Lab Investig. 1984;51:333–42.
Rajappan K, Rimoldi OE, Camici PG, et al. Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation. 2003;107:3170–5.
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II—causal mechanisms and treatment. Circulation. 2002;105:1503–8.
Hess OM, Ritter M, Schneider J, Grimm J, Turina M, Krayenbuehl HP. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. Circulation. 1984;69:855–65.
Gunther S, Grossman W. Determinants of ventricular function in pressure-overload hypertrophy in man. Circulation. 1979;59:679–88.
Schwartz LS, Goldfischer J, Sprague GJ, Schwartz SP. Syncope and sudden death in aortic stenosis. Am J Cardiol. 1969;23:647–58.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Gulino, S., Di Landro, A., Indelicato, A. (2018). Aortic Stenosis: Epidemiology and Pathogenesis. In: Tamburino, C., Barbanti, M., Capodanno, D. (eds) Percutaneous Treatment of Left Side Cardiac Valves. Springer, Cham. https://doi.org/10.1007/978-3-319-59620-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-59620-4_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59619-8
Online ISBN: 978-3-319-59620-4
eBook Packages: MedicineMedicine (R0)